Bluejay Diagnostics (BJDX) Debt to Equity (2020 - 2021)
Bluejay Diagnostics recorded quarterly Debt to Equity of $0.0 in Q4 2021, up 100.09% quarter-over-quarter from -$0.11 in Q3 2021, and up 100.33% year-over-year from $0.0 in Q4 2020.
Bluejay Diagnostics' Debt to Equity history runs 2 years deep, the most recent figure standing at $0.0 for Q4 2021.
- In Q4 2021, Debt to Equity rose 100.33% year-over-year to $0.0; the TTM figure through Dec 2021 stood at $0.0 (up 100.33% YoY), while the FY2021 annual figure was $0.0, up 100.33% from the prior year.
- Debt to Equity came in at $0.0 for Q4 2021 at Bluejay Diagnostics, up from -$0.11 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.0 in Q4 2021 to a low of -$0.11 in Q3 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 0.65 |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 0.64 |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 0.57 |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 0.42 |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.06 |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 0.95 |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 0.27 |
| 10 | Bluejay Diagnostics | 572,394.44 | -3.11 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 0.00 |
| Sep 30, 2021 | -0.11 |
| Dec 31, 2020 | -0.03 |